HP1 β is a biomarker for breast cancer prognosis and PARP inhibitor therapy

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Lee, Young Ho ^a   Liu, Xiyong ^a   Qiu, Fuming ^b   O'Connor, Timothy R ^a   Yen, Yun ^a   Ann, David K ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1ALPHA; HETEROCHROMATIN PROTEIN 1BETA; HETEROCHROMATIN PROTEIN 1GAMMA; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VELIPARIB; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN P53; HETEROCHROMATIN-SPECIFIC NONHISTONE CHROMOSOMAL PROTEIN HP-1; NONHISTONE PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA MINING; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MCF 7 CELL LINE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTION; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; AGE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER CELL LINE; CELL DEATH; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GENE; HP1BETA GENE; SURVIVAL RATE; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MCF-7 CELLS; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 84929492504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/joumal.pone.0121207     Document Type: Article

References (45)

1. Arranz EE, Vara JA, Gamez-Pozo A, Zamora P. Gene signatures in breast cancer: current and future uses. Translational oncology. 2012;5(6):398-403. PMID: 23323153
2. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nature reviews Cancer. 2005;5(8):591-602. PMID: 16056258
3. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6. PMID: 11823860
4. Perou CM, Sorlie T, Eisen MB, vande Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. PMID: 10963602
5. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. The Journal of pathology. 2010;220(2):263-80. doi: 10.1002/path.2648 PMID: 19927298
6. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi: 10.1038/nature11412 PMID: 23000897
7. Adamo B, Anders CK. Stratifying triple-negative breast cancer: which definition (s) to use? Breast cancer research: BCR. 2011;13(2):105. doi: 10.1186/bcr2852 PMID: 21457488
8. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31(6):961-7. doi: 10.1093/carcin/bqq069 PMID: 20400477
9. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nature reviews Cancer. 2004;4(10):814-9. PMID: 15510162
10. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, etal. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer research. 2006;66(16):8109-15. PMID: 16912188
11. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell cycle. 2011;10(8):1192-9. PMID: 21487248
12. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature. 2005;434(7035):913-7. PMID: 15829966
13. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21. PMID: 15829967
14. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine. 2009;361-(2):123-34. doi: 10.1056/NEJMoa0900212 PMID: 19553641
15. Chalasani P, Livingston R. Differential Chemotherapeutic Sensitivity for Breast Tumors With "BRCA-ness": A Review. The oncologist. 2013.
16. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concepttrial. Lancet. 2010;376(9737):235-44. doi: 10.1016/S0140-6736 (10) 60892-6 PMID: 20609467
17. Lee YH, Kuo CY, Stark JM, Shih HM, Ann DK. HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response. Nucleic acids research. 2013;41(11):5784-98. doi: 10.1093/nar/qkt231 PMID: 23589625
18. Eissenberg JC, Elgin SC. The HP1 protein family: getting agrip on chromatin. Current opinion in genetics & development. 2000;10(2):204-10.
19. Hiragami K, Festenstein R. Heterochromatin protein 1: a pervasive controlling influence. Cellular and molecular life sciences: CMLS. 2005;62(23):2711-26. PMID: 16261261
20. Dinant C, Luijsterburg MS. The emerging role of HP1 in the DNA damage response. Molecular and cellular biology. 2009;29(24):6335-40. doi: 10.1128/MCB.01048-09 PMID: 19805510
21. Ball AR Jr., Yokomori K. Revisiting the role of heterochromatin protein 1 in DNA repair. The Journal of cell biology. 2009;185(4):573-5. doi: 10.1083/icb.200904033 PMID: 19451270
22. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, et al. Gene expression predictors of breast cancer outcomes. Lancet. 2003;361(9369):1590-6. Epub 2003/05/16. PMID: 12747878
23. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. PMID: 12490681
24. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(10):3738-43. PMID: 15701700
25. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, et al. Discovery of the Poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. Journal of medicinal chemistry. 2009;52(2):514-23. doi: 10.1021/jm801171j PMID: 19143569
26. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-27. Epub 2006/12/13. PMID: 17157791
27. Clark CC, Weitzel JN, O'Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Molecular cancer therapeutics. 2012;11(9):1948-58. doi: 10.1158/1535-7163. MCT-11-0597 PMID: 22778154
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(36):9067-72.
29. Dialynas GK, Vitalini MW, Wallrath LL. Linking Heterochromatin Protein 1 (HP1) to cancer progression. Mutation research. 2008;647(1-2):13-20. doi: 10.1016/i.mrfmmm.2008.10.008 PMID: 18983859
30. Kirschmann DA, Lininger RA, Gardner LM, Seftor EA, Odero VA, Ainsztein AM, et al. Down-regulation of HP1 Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer research. 2000;60(13):3359-63. PMID: 10910038
31. De Koning L, Savignoni A, Boumendil C, Rehman H, Asselain B, Sastre-Garau X, et al. Heterochromatin protein 1 alpha: a hallmark of cell proliferation relevant to clinical oncology. EMBO molecular medicine. 2009;1(3):178-91. doi: 10.1002/emmm.200900022 PMID: 20049717
32. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast cancer research: BCR. 2011;13(2):R22. doi: 10.1186/bcr2834 PMID: 21366896
33. Slezak J, Truong M, Huang W, Jarrard D. HP1 gamma expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy. BMC cancer. 2013;13:148. doi: 10.1186/1471-2407-13-148 PMID: 23522301
34. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-52. doi: 10.1038/nature10983 PMID: 22522925
35. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. Journal of cellular physiology. 2000;182(3):311-22. PMID: 10653597
36. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(28):7212-20. PMID: 16192605
37. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? Cancer. 2003;97(5):1321-31. PMID: 12599241
38. Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2011;22(3):500-2.
39. Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast cancer research and treatment. 2013;139(2):539-52. doi: 10.1007/s10549-013-2560-8 PMID: 23674192
40. de Azambuja E, Cardoso F, de Castro G Jr., Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. British journal of cancer. 2007;96(10):1504-13. PMID: 17453008
41. Kametaka A, Takagi M, Hayakawa T, Haraguchi T, Hiraoka Y, Yoneda Y. Interaction of the chromatin compaction-inducing domain (LR domain) of Ki-67 antigen with HP1 proteins. Genes Cells. 2002;7-(12):1231-42. PMID: 12485163
42. Scholzen T, Endl E, Wohlenberg C, vander Sar S, Cowell IG, Gerdes J, et al. The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher-order chromatin structure. The Journal of pathology. 2002;196(2):135-44. PMID: 11793364
43. Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, et al. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PloSone. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042 PMID: 22253870
44. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. The oncologist. 2012;17-(7):956-62. doi: 10.1634/theoncoloqist.2012-0028 PMID: 22673632
45. Bast RC Jr., Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(22):3545-8.